Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Leap Therapeutics Inc Market Cap
From what 4 stock analysts predict, the share price for Leap Therapeutics Inc (LPTX) might increase by 259.97% in the next year. This is based on a 12-month average estimation for LPTX. Price targets go from $5.5 to $16. The majority of stock analysts believe LPTX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assignedLPTX 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Leap Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on LPTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of LPTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5.5 | Reiterates | Nov 15, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5.5 | Reiterates | Aug 13, 2024 |
| Tony Butler Rodman & Renshaw | Buy | $8 | Initiates | Jun 28, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5.5 | Maintains | May 14, 2024 |
| Joel Beatty Baird | Outperform | $9 | Maintains | Mar 19, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 19, 2024 |
| Mara Goldstein Mizuho | Buy | $12 | Maintains | Nov 20, 2023 |
| Steven Seedhouse Raymond James | Outperform | $17.5 | Maintains | Nov 14, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $7 | Maintains | Aug 15, 2023 |
| Joel Beatty Baird | Outperform | $20 | Maintains | Aug 15, 2023 |
| Steven Seedhouse Raymond James | Outperform | $18.5 | Maintains | Jul 13, 2023 |
| Steven Seedhouse Raymond James | Outperform | $17 | Maintains | Jun 23, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $2.5 | Reiterates | May 16, 2023 |
| Mara Goldstein Mizuho | Buy | $2 | Reiterates | Apr 13, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $2.5 | Reiterates | Mar 27, 2023 |
| Steven Seedhouse Raymond James | Outperform | $2 | Maintains | Mar 27, 2023 |
| Mara Goldstein Mizuho | Buy | $2 | Maintains | Mar 17, 2023 |
| Mara Goldstein Mizuho | Buy | $3 | Maintains | Jan 27, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $2.5 | Maintains | Jan 18, 2023 |
| Steven Seedhouse Raymond James | Outperform | $2.5 | Maintains | Nov 11, 2022 |
When did it IPO
2017
Staff Count
54
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Douglas E. Onsi J.D.
Market Cap
$121.1M
In 2023, LPTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that LPTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Leap Therapeutics, Inc. (Nasdaq: LPTX) announced a leadership update on November 26, 2024, as it continues to focus on targeted and immuno-oncology therapeutics.
Why It Matters - Douglas E. joining Leap Therapeutics could signal strategic leadership changes, potentially impacting future innovations and stock performance in the biotech sector.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Leap Therapeutics, Inc. (Nasdaq:LPTX) reported its third-quarter financial results for 2024, focusing on targeted and immuno-oncology therapeutics.
Why It Matters - Leap Therapeutics' Q3 financial results can impact stock performance, indicating the company's growth prospects and investor confidence in its therapeutics pipeline.
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Leap Therapeutics has completed enrollment of 188 patients in Part B of the DeFianCe study, evaluating DKN-01 with bevacizumab and chemotherapy for advanced colorectal cancer.
Why It Matters - The completion of patient enrollment in a key study for DKN-01 signals progress in clinical development, which could impact Leap Therapeutics' valuation and stock performance based on trial outcomes.
Thu, 22 Aug 2024
Sentiment - POSITIVE
Source - 24/7 Wall Street
Summary - Biotech stocks are highlighted as favorable investment options, though specific reasons for this preference are not detailed in the excerpt.
Why It Matters - Interest in biotech stocks can signal potential growth and innovation in the sector, attracting investment and influencing market trends. Positive sentiment may drive stock prices higher.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Leap Therapeutics, Inc. (Nasdaq:LPTX) announced its Q2 2024 financial results, focusing on targeted and immuno-oncology therapeutics. Further details on financial performance were not provided.
Why It Matters - Leap Therapeutics' financial results could indicate growth potential or challenges in their biotech initiatives, influencing stock performance and investor sentiment.
Mon, 13 May 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Leap Therapeutics, Inc. (Nasdaq:LPTX) reported its Q1 financial results for 2024, focusing on targeted and immuno-oncology therapies. Details on performance are forthcoming.
Why It Matters - Leap Therapeutics’ Q1 financial results can impact stock performance and investor sentiment, reflecting the company's growth potential and market position in the biotech sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
